Cargando…
LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
BACKGROUND: It is well known that nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance (IR). LB100, a serine/threonine protein phosphatase 2A (PP2A) inhibitor, is closely related to IR. However, there is little data regarding its direct influence on NAFLD. AIM: To elucidate...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906208/ https://www.ncbi.nlm.nih.gov/pubmed/31832001 http://dx.doi.org/10.3748/wjg.v25.i45.6607 |